Physician

Jeremy P Pepin, M.D.

According to 2025 Medicare claims, Jeremy Pepin, M.D. (NPI: 1073995973) practices nephrology in the Omaha, NE-IA market, with the plurality of this provider's patient population coming from Pottawattamie, IA. This provider's primary affiliated billing organization is ADVANCED KIDNEY CARE PLLC (NPI: 1154193712; TIN: 93-4107222) and primary practice location at 51503-3128. Pepin is affiliated with the NPG Health Collaborative LLC (ACO ID: A3287), Caravan Health ACO 50 LLC (ACO ID: A5160), Main Street Rural Health Maple ACO LLC (ACO ID: A5401), and CoreHealth Alliance LLC (ACO ID: A5645), participating under the MSSP model.

Pepin's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 285 traditional Medicare patients, billed 1,077 HCPCS/CPT codes, and received $154,724 in Medicare payments. The top billing code was 99205 (New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more). Part D data shows 2,359 prescription claims across 370 beneficiaries totaling $771,953 in drug costs, led by Farxiga (Dapagliflozin Propanediol). DME data shows 28 claims. Open Payments data shows 51 records totaling $11,104. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved up and down with repeated peaks and valleys, starting at $59,150 and ending at $154,724. Concurrently, Part D prescription costs have risen steadily, from $2,597 to $771,953. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	233	2,268	$59,150
2021	436	2,209	$141,899
2022	378	1,326	$167,879
2023	287	967	$117,483
2024	285	1,077	$154,724

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	18	66	$2,597
2016	46	702	$28,834
2017	44	697	$63,300
2018	53	417	$37,957
2019	42	213	$10,307
2020	80	284	$20,301
2021	139	664	$61,404
2022	190	892	$93,668
2023	195	1,227	$244,004
2024	370	2,359	$771,953

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	28	$442
2022	N/R	77	$1,397
2023	N/R	72	$1,440
2024	N/R	28	$404

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99205	New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more	84	84	$151
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	81	103	$131
99223	Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes	40	53	$127
99204	New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more	35	35	$117
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	109	155	$92

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Farxiga	Dapagliflozin Propanediol	400	15,789	$293,509
Kerendia	Finerenone	163	6,397	$137,788
Xphozah	Tenapanor Hcl	18	780	$79,309
Ozempic	Semaglutide	39	2,763	$46,944
Lokelma	Sodium Zirconium Cyclosilicate	13	689	$16,688

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J7507	Tacrolimus, immediate release, oral, 1 mg	N	N/R	14	$254
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	14	$150

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	51	$11,104	AstraZeneca Pharmaceuticals LP
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Jeremy P. Pepin, M.D.?

Tedicare shows public-source Medicare data for Jeremy P. Pepin, M.D. (NPI 1073995973), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Jeremy P. Pepin, M.D. have ACO affiliation data?

Jeremy P. Pepin, M.D. is shown with ACO affiliation data for NPG Health Collaborative LLC (MSSP, ACO ID A3287), Caravan Health ACO 50 LLC (MSSP, ACO ID A5160), Main Street Rural Health Maple ACO LLC (MSSP, ACO ID A5401), and CoreHealth Alliance LLC (MSSP, ACO ID A5645).

What billing organization is linked to Jeremy P. Pepin, M.D.?

Jeremy P. Pepin, M.D. is linked to ADVANCED KIDNEY CARE PLLC (billing NPI 1154193712) in the available physician profile data.

Does Jeremy P. Pepin, M.D. have Open Payments data?

Jeremy P. Pepin, M.D. has 51 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.